Supplementary Materials:



Figure S1. ¹H-NMR spectrum of PEG4k-TsCl.



Figure S2. ¹H-NMR spectrum of PEG5k-TsCl.



Figure S3. ¹H-NMR spectrum of PEG4k-PR.



Figure S4. ¹H-NMR spectrum of PEG5k-PR.



Figure S5. ¹³C-NMR spectrum of PEG4k-PR.



Figure S6. The ¹³C-NMR spectrum of PEG5k-PR.

Compound _	Initial		Ending (120 min)		Percentage of concentration
	As/Ai	Conc. (µM)	As/Ai	Conc. (µM)	change
PR	0.32 ± 0.01	56.90 ± 1.10	0.31 ± 0.01	56.11 ± 1.57	1.38%
PEG4kPR	0.54 ± 0.01	54.87 ± 2.44	0.54 ± 0.01	54.29 ± 0.61	1.07%
PEG5k-PR	0.87 ± 0.01	56.47 ± 0.65	0.86 ± 0.01	55.58 ± 0.37	1.57%
Atenolol	0.71 ± 0.01	105.19 ± 0.96	0.71 ± 0.01	105.93 ± 0.61	0.75
Ketoprofen	1.11 ± 0.02	101.27 ± 1.22	1.09 ± 0.01	100.28 ± 0.96	0.97
Metoprolol	0.79 ± 0.02	103.62 ± 2.29	0.76 ± 0.01	102.12 ± 0.58	1.46

Table S1. Concentration changes of all compounds before and after the shaker bath experiment. Data are shown as mean \pm SD, n = 3.

As: HPLC peak area of compound.

Ai: HPLC peak area of internal standard.

Percentage of concentration change: (Initial Conc.-Ending Conc.) / Initial Conc.



Figure S7. Calibration line of PR (MW = 354) in Krebs–Ringer buffer.



Figure S8. Calibration line of PEG4k-PR (MW = 4354) in Krebs–Ringer buffer.



Figure S9. Calibration line of PEG5k-PR (MW = 5354) in Krebs–Ringer buffer.



Figure S10. Calibration line of atenolol (MW = 266) in Krebs–Ringer buffer.



Figure S11. Calibration line of ketoprofen (MW = 254) in Krebs–Ringer buffer.



Figure S12. Calibration line of metoprolol (MW = 684) in Krebs–Ringer buffer.